This study was supported by NIDA Clinical Trials Network grant U10 DA13035 (Hu, Campbell, and Hien; Principal Investigators: Edward Nunes and John Rotrosen). This research was also supported in part by R03 DA034102 (McHugh), U10 DA015831 (Weiss), and K24 DA022288 (Weiss).
Changes in Sleep Disruption in the Treatment of Co-Occurring Posttraumatic Stress Disorder and Substance Use Disorders
Version of Record online: 28 JAN 2014
Copyright © 2014 International Society for Traumatic Stress Studies
Journal of Traumatic Stress
Volume 27, Issue 1, pages 82–89, February 2014
How to Cite
McHugh, R. K., Hu, M.-C., Campbell, A. N. C., Hilario, E. Y., Weiss, R. D. and Hien, D. A. (2014), Changes in Sleep Disruption in the Treatment of Co-Occurring Posttraumatic Stress Disorder and Substance Use Disorders. J. Traum. Stress, 27: 82–89. doi: 10.1002/jts.21878
- Issue online: 10 FEB 2014
- Version of Record online: 28 JAN 2014
- NIDA Clinical Trials Network. Grant Numbers: U10 DA13035R03, DA034102 (McHugh), U10 DA015831, K24 DA022288
Sleep disruption appears not only to reflect a symptom of posttraumatic stress disorder (PTSD), but also a unique vulnerability for its development and maintenance. Studies examining the impact of psychosocial treatments for PTSD on sleep symptoms are few and no studies to date of which we are aware have examined this question in samples with co-occurring substance use disorders. The current study is a secondary analysis of a large clinical trial comparing 2 psychological treatments for co-occurring PTSD and substance use disorders. Women (N = 353) completed measures of PTSD at baseline, end of treatment, and 3-, 6-, and 12-month follow-ups. Results indicated that the prevalence of insomnia, but not nightmares, decreased during treatment, and that 63.8% of participants reported at least 1 clinical-level sleep symptom at the end of treatment. Improvement in sleep symptoms during treatment was associated with better overall PTSD outcomes over time, χ2(1) = 33.81, p < .001. These results extend the existing literature to suggest that residual sleep disruption following PTSD treatment is common in women with co-occurring PTSD and substance use disorders. Research on the benefits of adding sleep-specific intervention for those with residual sleep disruption in this population may be a promising future direction.
Traditional and Simplified Chinese Abstracts by AsianSTSS
撮要：睡眠障礙除了是創傷後壓力症(PTSD)的症狀，亦獨特地影響它的發展和持續性。針對PTSD睡眠症狀的心理社會治療研究很少，而探討與物質濫用共病樣本的相關研究更是未有的。本研究是一個比對兩種治療PTSD共病物質濫用的心理治療的大型研究二次分析。全部樣本為女性(N=353), 並完成在：基準、治療結束、三個月、六個月及十二個月覆診期的PTSD 量度。結果顯示在治療期間失眠(而非惡夢)流行率下降，而63.8%人在治療結束時有最少一種臨床睡眠症狀。治療中睡眠症狀改進與綜合PTSD結果變好有相關，X2=33.81, p< .001。研究結果加強現存文庫中患上PTSD 共病物質濫用的婦女在PTSD 治療後殘存睡眠障礙的實證。未來研究應對殘存睡眠障礙的PTSD共病物質濫用者添加特定睡眠介入治療的益處作探討。
撮要：睡眠障碍除了是创伤后压力症(PTSD)的症状，亦独特地影响它的发展和持续性。针对PTSD睡眠症状的心理社会治疗研究很少，而探讨与物质滥用共病样本的相关研究更是缺乏的。本研究是一个比较两种治疗PTSD共病物质滥用的心理治疗的大型研究二次分析。全部样本为女性(N=353), 并完成在：基准、治疗结束、三个月、六个月及十二个月覆诊期的PTSD 量度。结果显示在治疗期间失眠(而非恶梦)流行率下降，而63.8%人在治疗结束时有最少一种临床睡眠症状。治疗中睡眠症状改进与综合PTSD结果变好有相关，X2=33.81, p< .001。研究结果加强现存文库中患上PTSD 共病物质滥用的妇女在PTSD 治疗后残存睡眠障碍的实证。未来研究应对残存睡眠障碍的PTSD共病物质滥用者添加特定睡眠介入治疗的益处作探讨。